A known CAD-associated miRNA, miR-92a, may mediate some ANRIL effects; ANRIL targets GATA2, MAP1B, and ARG1 were found to require miR-92a, placing this miRNA downstream of ANRIL for some atherogenic effects (69). The gene discussed is CDKN2B-AS1; the disease is coronary artery disorder.